At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find them.
|Videos|August 12, 2011
ASCO: Controversies in Phase I Clinical Trials
Author(s)Steve Joffe, MD
Steve Joffe, MD discusses the ethical challenges and controversies in phase I clinical cancer trials.
Advertisement
Steve Joffe, MD discusses the ethical challenges and controversies in phase I clinical cancer trials: how physicians should present these clinical trials to patients-phase I trials typically have very low response rates (5% to 10%)-and explain their purpose without exaggerating the likely results.
Advertisement
Related to this article
At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC surveillance.
At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and how navigators can help.
Surveillance guidelines limited to cirrhosis may miss up to a third of patients with MASLD-related HCC, according to Daniel Q. Huang, MBBS, PhD.
Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.
At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.
Pierre Gholam, MD, discussed how navigation, molecular profiling, and hub-and-spoke models can help liver tumor boards turn recommendations into care.
Neil Mehta, MD, and Laura Kulik, MD, discussed patient selection, washout timing, and posttransplant monitoring for immunotherapy before liver transplant.
Advertisement
Advertisement
Trending on CancerNetwork
1
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
2
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
3
Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML
4
Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant
5